Generics Industry Counts Cost Of Stormy Second Quarter
Teva, Sandoz And Mylan Saw Q2 Industry Downturn Coming
As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.
